Phase 3 MAGNITUDE study: Results from second interim analysis of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without HRR gene alterations

Quality of life in patients with multiple myeloma treated with selinexor who had dose reductions: A subgroup analysis of the BOSTON study

Identification and Management of Adverse Events Associated With Ciltacabtagene Autoleucel for Treatment of Multiple Myeloma in CARTITUDE-2

Patients receiving short run-in treatment (≤2 months) with abiraterone acetate and prednisone (AAP) showed similar benefit from niraparib and AAP in the phase 3 MAGNITUDE study with metastatic castration-resistant prostate cancer and HRR gene alterations

Minimal Residual Disease Negativity as a Measure of Response to Ciltacabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

In and Out: The Convenience of Subcutaneous Epcoritamab in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Ribociclib Safety, Monitoring, and Management Strategies in Advanced Breast Cancer

Darolutamide Can Be Effectively and Safely Administered in Combination With Androgen-Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Is There Cancer-Related Cognitive Impairment in Older Adults with Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax Chemotherapy?

Patient retention and physician engagement strategies during the COVID-19 pandemic in the phase 3 ATLAS study of apalutamide added to androgen deprivation therapy in high-risk localized or locally advanced prostate cancer

Increasing the Awareness of Nurses on Evolving Cell Therapies

Perceived Cognitive Functioning is Associated with Adherence to an Aerobic Exercise Intervention for Women with Early-Stage Breast Cancer

Cutaneous Toxicities with Amivantamab for Non-small Cell Lung Cancer (NSCLC) with Exon 20 Insertion Mutation (ex20ins): A Practical Guide and Best Practices for Management

ROMAN: Phase 3 Trial of Avasopasem Manganese (GC4419) for Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC)

Outcomes by Prostate-Specific Antigen Level in Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide Plus Androgen Deprivation Therapy and Implications for Clinical Practice